Hino M, Ishiko O, Honda K I, Yamane T, Ohta K, Takubo T, Tatsumi N
Department of Clinical Haematology, Osaka City University Medical School, Osaka, Japan.
Br J Haematol. 2000 Jan;108(1):194-5. doi: 10.1046/j.1365-2141.2000.01818.x.
Human parvovirus B19 infection has been shown to be transmissible by blood and blood products and to result in transient aplastic crisis in patients with rapid red cell turnover. We report three cases of iatrogenic parvovirus B19 infection resulting from the use of the same batch of fibrin sealant under operation. Fibrin sealant, which is a typical haemostatic agent produced from blood, has been used during surgery. Human parvovirus is resistant to existing virus-inactivating techniques, suggesting that infection may occur from blood products contaminated with it. Use of recombinant products for these proteins may thus be necessary.
人细小病毒B19感染已被证明可通过血液及血液制品传播,并可导致红细胞快速更新的患者发生短暂性再生障碍危象。我们报告了3例因手术中使用同一批次纤维蛋白胶而导致医源性细小病毒B19感染的病例。纤维蛋白胶是一种典型的由血液制成的止血剂,已在手术中使用。人细小病毒对现有的病毒灭活技术具有抗性,这表明感染可能源于被其污染的血液制品。因此,可能有必要使用这些蛋白质的重组产品。